Zolmitriptan is under clinical development by MapLight therapeutics and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zolmitriptan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zolmitriptan overview

Zolmitriptan is under development for the treatment of autism spectrum disorders and agitation and aggression in Alzheimer's Disease. The drug candidate is administered by oral route as tablet.

MapLight therapeutics overview

MapLight therapeutics. (formerly Alvarado Therapeutics, Inc.), is a biopharmaceutical company focusing on drug discovery for diseases of the central nervous system. The company is headquartered in United States.

For a complete picture of Zolmitriptan’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.